Case report: A therapeutic attempt to treat Morbihan disease with Baricitinib
Luying Chen,
Yanjuan Duan,
Liang Zhao,
Miao Xu,
Yeqiang Liu,
Xiaoxiang Zhai
Affiliations
Luying Chen
Department of Dermatology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China
Yanjuan Duan
Department of Dermatology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China
Liang Zhao
Department of Dermatology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China
Miao Xu
Department of Dermatology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China
Yeqiang Liu
Department of Dermatopathology, Shanghai Skin Disease Hospital of Tongji University School of Medicine, Shanghai, China
Xiaoxiang Zhai
Department of Dermatology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; Corresponding author. Address: No. 358, Datong Road, Shanghai, China.
A woman in her thirties who had been diagnosed with Morbihan disease did not notice a significant improvement in her condition after receiving years of treatment. Our decision to use Baricitinib helped her to achieve a better outcome. To our knowledge, this is the first study to use Baricitinib in Morbihan disease, although JAK inhibitors have already been successfully used before. It is hoped that our case report will provide new treatment options for Morbihan disease therapy.
